XBiotech Inc. (FRA:4XB)
Germany · Delayed Price · Currency is EUR 1.810
-0.010 (-0.55%)
At close: Dec 1, 2025
XBiotech Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '25 Sep 30, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
Operating Revenue | - | - | - | 4.01 | 18.39 | 43.98 | Upgrade |
Other Revenue | - | - | - | - | - | 0.02 | Upgrade |
| - | - | - | 4.01 | 18.39 | 44 | Upgrade | |
Revenue Growth (YoY) | - | - | - | -78.20% | -58.19% | - | Upgrade |
Cost of Revenue | - | - | - | 0.65 | 5.82 | 34.55 | Upgrade |
Gross Profit | - | - | - | 3.36 | 12.57 | 9.45 | Upgrade |
Selling, General & Admin | 4.83 | 4.71 | 4.66 | 6.31 | 9.39 | 18.2 | Upgrade |
Research & Development | 29.85 | 37.76 | 32.85 | 31.54 | 28.27 | 9.53 | Upgrade |
Operating Expenses | 34.68 | 42.47 | 37.51 | 37.85 | 37.66 | 27.73 | Upgrade |
Operating Income | -34.68 | -42.47 | -37.51 | -34.49 | -25.08 | -18.28 | Upgrade |
Interest Expense | -0.29 | -0.81 | - | - | - | - | Upgrade |
Interest & Investment Income | 6.56 | 9.81 | 10.42 | 3.82 | 0.47 | 2.46 | Upgrade |
Currency Exchange Gain (Loss) | -1.94 | -5.53 | 1.89 | -2.8 | -0.71 | 3.5 | Upgrade |
Other Non Operating Income (Expenses) | 1.31 | 0.43 | 0.88 | -0.12 | -0.13 | -0.5 | Upgrade |
EBT Excluding Unusual Items | -29.04 | -38.56 | -24.31 | -33.59 | -25.46 | -12.83 | Upgrade |
Pretax Income | -29.04 | -38.56 | -24.31 | -33.59 | -25.46 | -12.83 | Upgrade |
Income Tax Expense | 0.12 | -0.03 | 0.24 | -0.69 | -8.04 | -1.61 | Upgrade |
Net Income | -29.16 | -38.53 | -24.56 | -32.9 | -17.41 | -11.22 | Upgrade |
Net Income to Common | -29.16 | -38.53 | -24.56 | -32.9 | -17.41 | -11.22 | Upgrade |
Shares Outstanding (Basic) | 30 | 30 | 30 | 30 | 30 | 31 | Upgrade |
Shares Outstanding (Diluted) | 30 | 30 | 30 | 30 | 30 | 31 | Upgrade |
Shares Change (YoY) | 0.09% | 0.07% | -0.00% | 1.32% | -2.53% | -33.45% | Upgrade |
EPS (Basic) | -0.96 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | Upgrade |
EPS (Diluted) | -0.96 | -1.26 | -0.81 | -1.08 | -0.58 | -0.36 | Upgrade |
Free Cash Flow | -23.85 | -32.27 | -19.09 | -15.41 | 65.92 | -68.88 | Upgrade |
Free Cash Flow Per Share | -0.78 | -1.06 | -0.63 | -0.51 | 2.19 | -2.23 | Upgrade |
Gross Margin | - | - | - | 83.77% | 68.36% | 21.48% | Upgrade |
Operating Margin | - | - | - | -860.10% | -136.36% | -41.54% | Upgrade |
Profit Margin | - | - | - | -820.45% | -94.67% | -25.50% | Upgrade |
Free Cash Flow Margin | - | - | - | -384.26% | 358.38% | -156.55% | Upgrade |
EBITDA | -32.93 | -40.73 | -35.77 | -31.88 | -22.43 | -16.04 | Upgrade |
EBITDA Margin | - | - | - | - | -121.96% | -36.45% | Upgrade |
D&A For EBITDA | 1.75 | 1.75 | 1.74 | 2.61 | 2.65 | 2.24 | Upgrade |
EBIT | -34.68 | -42.47 | -37.51 | -34.49 | -25.08 | -18.28 | Upgrade |
EBIT Margin | - | - | - | - | -136.36% | -41.54% | Upgrade |
Revenue as Reported | - | - | - | 4.01 | 18.39 | 44 | Upgrade |
Source: S&P Global Market Intelligence. Standard template. Financial Sources.